Brief: Bristol-Myers' Opdivo Shows Significant Overall Survival Benefit Vs. Chemotherapy In Esophageal Cancer Patients

ONO PHARMACEUTICAL

30/09/2019 15:42

Sept 30 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * OPDIVO (NIVOLUMAB) DEMONSTRATES STATISTICALLY SIGNIFICANT
OVERALL SURVIVAL BENEFIT VERSUS CHEMOTHERAPY IN PATIENTS WITH
ADVANCED ESOPHAGEAL CANCER
    * BRISTOL-MYERS SQUIBB CO - OPDIVO DEMONSTRATED A 23%
REDUCTION IN
RISK OF DEATH
    * BRISTOL-MYERS SQUIBB CO -  OPDIVO DEMONSTRATED 2.5-MONTH
IMPROVEMENT IN MEDIAN OVERALL SURVIVAL COMPARED TO CHEMOTHERAPY
    * BRISTOL-MYERS SQUIBB CO - FOR PRIMARY ENDPOINT OF OVERALL
SURVIVAL (OS), OPDIVO DEMONSTRATED A STATISTICALLY SIGNIFICANT
IMPROVEMENT OVER CHEMOTHERAPY
    * BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF OPDIVO IN
TRIAL WAS
CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN ESCC AND OTHER
SOLID TUMORS

Source text for Eikon:  ID:nBw8ZgVyQa 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))